PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
N Engl J Med. Author manuscript; available in PMC 2010 August 25.
Published in final edited form as:
PMCID: PMC2928221
NIHMSID: NIHMS227888

Nicotine Addiction

Cigarette smoking remains a leading cause of preventable disease and premature death in the United States and other countries. On average, 435,000 people in the United States die prematurely from smoking-related diseases each year; overall, smoking causes 1 in 5 deaths. The chance that a lifelong smoker will die prematurely from a complication of smoking is approximately 50%.1

Tobacco use is a major cause of death from cancer, cardiovascular disease, and pulmonary disease. Cigarette smoking is also a risk factor for respiratory tract and other infections, osteoporosis, reproductive disorders, adverse postoperative events and delayed wound healing, duodenal and gastric ulcers, and diabetes. In addition, smoking has a strong association with fire-related and trauma-related injuries. Smoking-caused disease is a consequence of exposure to toxins in tobacco smoke. Although nicotine plays a minor role, if any, in causing smoking-induced diseases, addiction to nicotine is the proximate cause of these diseases.

Currently, about 45 million Americans smoke tobacco. Seventy percent of smokers say they would like to quit, and every year, 40% do quit for at least 1 day.2 Some highly addicted smokers make serious attempts to quit but are able to stop only for a few hours.3 Moreover, the 80% who attempt to quit on their own return to smoking within a month, and each year, only 3% of smokers quit successfully. Unfortunately, the rate at which persons — primarily children and adolescents — become daily smokers nearly matches the quit rate, so the prevalence of cigarette smoking has declined only very slowly in recent years.2

This article focuses on nicotine as a determinant of addiction to tobacco and the pharmacologic effects of nicotine that sustain cigarette smoking. Tobacco addiction (like all drug addictions) involves the interplay of pharmacology, learned or conditioned factors, genetics, and social and environmental factors (including tobacco product design and marketing)4 (Fig. 1). The pharmacologic reasons for nicotine use are enhancement of mood, either directly or through relief of withdrawal symptoms, and augmentation of mental or physical functions.

Figure 1
The Biology of Nicotine Addiction

BRAIN MECHANISMS

NICOTINIC ACETYLCHOLINE RECEPTORS

Inhalation of smoke from a cigarette distills nicotine from the tobacco in the cigarette. Smoke particles carry the nicotine into the lungs, where it is rapidly absorbed into the pulmonary venous circulation. The nicotine then enters the arterial circulation and moves quickly from the lungs to the brain, where it binds to nicotinic cholinergic receptors (ligand-gated ion channels that normally bind acetylcholine). The binding of nicotine at the interface between two subunits of the receptor opens the channel, thereby allowing the entry of sodium or calcium.5 The entry of these cations into the cell further activates voltage-dependent calcium channels, allowing more calcium to enter. One of the effects of the entry of calcium into a neuron is the release of neurotransmitters.

The nicotinic cholinergic receptor consists of five subunits.6 The mammalian brain expresses nine α subunits (α2 through α10) and three β subunits (β2 through β4). The most abundant receptors are α4β2, α3β4, and α7, the latter of which are homomeric. The α4β2* receptor (the asterisk indicates that other subunits may be present in this receptor) is the principal mediator of nicotine dependence. In mice, disruption of the β2 subunit gene eliminates the behavioral effects of nicotine; reinserting the gene into the ventral tegmental area restores behavioral responses to nicotine.7,8 The α4 subunit is an important determinant of sensitivity to nicotine. A mutation affecting a single nucleotide in the pore-forming region of the mouse receptor gene makes it hypersensitive to the effects of nicotine.9 Other subunits can form functional receptors. The presence of an α5 subunit combined with α4β2 increases calcium conductance seven times; α5 gene variants also alter nicotine responsiveness in cultured human cells.10,11 The α3β4 subtype probably mediates the cardiovascular effects of nicotine.12 The α7 homomeric receptors are involved in rapid synaptic transmission and long-term potentiation to dopaminergic neurons at excitatory inputs and have a role in learning and sensory gating.1316

NICOTINE AND NEUROTRANSMITTER RELEASE

Stimulation of nicotinic cholinergic receptors releases a variety of neurotransmitters in the brain.5,17 One of them, dopamine, signals a pleasurable experience and is critical for the reinforcing effects (effects that promote self-administration) of nicotine and other drugs of abuse, as well as for compelling drives such as eating.18 Experimentally induced lesions in dopamine-releasing neurons prevent self-administration of nicotine in rats. Nicotine releases dopamine in the mesolimbic area, the corpus striatum, and the frontal cortex (Fig. 2). The dopaminergic neurons in the ventral tegmental area of the midbrain and in the shell of the nucleus accumbens are critical in drug-induced reward (both regions have a role in perceptions of pleasure and reward).6,18

Figure 2
Role of the Mesolimbic Dopamine System in Nicotine Activity

Nicotine also augments both glutamate release, which facilitates the release of dopamine, and γ-aminobutyric acid (GABA) release, which inhibits dopamine release.15,16 With long-term exposure to nicotine, some nicotinic cholinergic receptors become desensitized but some do not. As a result, GABA-mediated inhibitory tone diminishes while glutamate-mediated excitation persists, thereby increasing excitation of dopaminergic neurons and enhancing responsiveness to nicotine.

A measure of the function of the reward system in rats is the threshold for electrical self-stimulation in the medial forebrain: a lower threshold indicates increased responsiveness to rewarding stimuli. Nicotine lowers the threshold for reward, an effect that can last for more than 30 days.19 It also increases activity in the prefrontal cortex, thalamus, and visual system, reflecting activation of corticobasal ganglia–thalamic brain circuits (part of the reward network), and releases dopamine in the striatum.20 Other neurotransmitters that may be involved in nicotine addiction are the hypocretins, neuropeptides produced in the lateral hypothalamus that regulate the stimulatory effects of nicotine on reward centers in the brain and modulate self-administration of nicotine in rodents.21

MONAMINE OXIDASE

Constituents of cigarette smoke other than nicotine contribute to nicotine addiction. Monoamine oxidases, enzymes located in catecholaminergic and other neurons, catalyze the metabolism of dopamine, norepinephrine, and serotonin. Condensation products of acetaldehyde in cigarette smoke with biogenic amines inhibit the activity of monoamine oxidase type A and monoamine oxidase type B, and there is evidence that inhibition of monoamine oxidase contributes to the addictiveness of smoking by reducing the metabolism of dopamine.22,23

NEUROADAPTATION

With repeated exposure to nicotine, neuroadaptation (tolerance) to some of the effects of nicotine develops.24 As neuroadaptation develops, the number of binding sites on the nicotinic cholinergic receptors in the brain increases, probably in response to nicotine-mediated desensitization of receptors.25 Desensitization — ligand-induced closure and unresponsiveness of the receptor — is believed to play a role in tolerance and dependence: the symptoms of craving and withdrawal begin in smokers when desensitized α4 β2* nicotinic cholinergic receptors become responsive during periods of abstinence, such as nighttime sleep.26 Nicotine binding of these receptors during smoking alleviates craving and withdrawal.

Cigarette smoking in amounts that are typical for daily smokers maintains near-complete saturation — and thus desensitization — of the α4 β2* nicotinic cholinergic receptors.27 Thus, smokers are probably attempting to avoid withdrawal symptoms when maintaining a desensitized state. By sustaining sufficient levels of plasma nicotine to prevent withdrawal symptoms, they also derive rewarding effects from the conditioned reinforcements associated with smoking, such as the taste and feel of smoke.28

Nicotine withdrawal causes anxiety and stress, both of which are powerful incentives to take up smoking again.29 The negative affect that typifies the response to nicotine withdrawal probably results in part from a cascade of events involving increased levels of extrahypothalamic corticotropin-releasing factor (CRF) and increased binding of CRF to corticotropin-releasing factor 1 (CRF1) receptors in the brain, thereby activating the CRF–CRF1 receptor system, which mediates responses to stress. In rats, anxiety-like behavior and the release of CRF in the central nucleus of the amygdala occur during nicotine withdrawal.30 CRF causes anxiety, whereas the pharmacologic blockade of CRF1 receptors inhibits the anxiogenic effects of nicotine withdrawal. The blockade of CRF1 receptors also prevents the increase in self-administration of nicotine that occurs during abstinence from forced nicotine administration in rats. Thus, both underactivity of the dopaminergic system and activation of the CRF–CRF1 receptor system contribute to the symptoms of nicotine withdrawal that often precipitate relapse.

CLINICAL ASPECTS OF NICOTINE ADDICTION

PSYCHOACTIVE EFFECTS OF NICOTINE

Nicotine induces pleasure and reduces stress and anxiety. Smokers use it to modulate levels of arousal and to control mood. Smoking improves concentration, reaction time, and performance of certain tasks. Relief from withdrawal symptoms is probably the primary reason for this enhanced performance and heightened mood.31 Cessation of smoking causes the emergence of withdrawal symptoms: irritability, depressed mood, restlessness, and anxiety.32 The intensity of these mood disturbances is similar to that found in psychiatric outpatients.33 Anhedonia — the feeling that there is little pleasure in life — can also occur with withdrawal from nicotine, and from other drugs of abuse.34

The basis of nicotine addiction is a combination of positive reinforcements, including enhancement of mood and avoidance of withdrawal symptoms (Fig. 3).35 In addition, conditioning has an important role in the development of tobacco addiction.

Figure 3
Molecular and Behavioral Aspects of Nicotine Addiction

CONDITIONED BEHAVIOR

When a person who is addicted to nicotine stops smoking, the urge to resume is recurrent and persists long after withdrawal symptoms dissipate. With regular smoking, the smoker comes to associate specific moods, situations, or environmental factors — smoking-related cues — with the rewarding effects of nicotine. Typically, these cues trigger relapse.

The association between such cues and the anticipated effects of nicotine, and the resulting urge to use nicotine, constitute a form of conditioning. Studies in animals show that nicotine exposure causes changes in the protein expression of brain cells and in their synaptic connections — a process termed neural plasticity — which underlie conditioning.36,37 Nicotine also enhances behavioral responses to conditioned stimuli, which may contribute to compulsive smoking.38 Furthermore, studies in nicotine-dependent rats show that conditioned stimuli associated with nicotine withdrawal increase the magnitude of withdrawal through an elevation of the brain’s reward threshold.39 Thus, cues associated with nicotine withdrawal can decrease the function of the brain’s reward systems.

The desire to smoke is maintained, in part, by such conditioning. Smokers usually take a cigarette after a meal, with a cup of coffee or an alcoholic drink, or with friends who smoke. When repeated many times, such situations become a powerful cue for the urge to smoke. Aspects of smoking itself — the manipulation of smoking materials, or the taste, smell, or feel of smoke in the throat — also become associated with the pleasurable effects of smoking.40,41 Even unpleasant moods can become conditioned cues for smoking: a smoker may learn that not having a cigarette provokes irritability and that smoking one provides relief. After repeated experiences like this, a smoker can sense irritability from any source as a cue for smoking. Functional imaging studies have shown that exposure to drug-associated cues activates cortical regions of the brain, including the insula (a structure in the cortex associated with certain basic emotions). Smokers who sustain damage to the insula (e.g., brain trauma) are more likely to quit smoking soon after the injury, and to remain abstinent, and are less likely to have conscious urges to smoke than smokers with brain injury that does not affect the insula.42

THE TOBACCO ADDICTION CYCLE

Smoking is a highly efficient form of drug administration. Inhaled nicotine enters the circulation rapidly through the lungs and moves into the brain within seconds. Rapid rates of absorption and entry into the brain cause a strongly felt “rush” and reinforce the effects of the drug. In animals, rapid administration of nicotine potentiates locomotor sensitization, which is linked to reward, and neuroplastic changes in the brain.43 The smoking process also provides rapid reinforcement and allows for precise dosing, making it possible for a smoker to obtain desired effects without toxicity. Unlike cigarettes, nicotine medications marketed to promote smoking cessation deliver nicotine slowly, and the risk of abuse is low.44 In addition to delivering nicotine to the brain quickly, cigarettes have been designed with additives and engineering features to enhance its addictiveness.45

There is considerable peak-to-trough oscillation in blood levels of nicotine from cigarette to cigarette. Nevertheless, it accumulates in the body over the course of 6 to 9 hours of regular smoking and results in 24 hours of exposure. Arteriovenous differences in nicotine concentrations during cigarette smoking are substantial, with arterial levels up to 10 times as high as venous levels.46 The persistence of nicotine in the brain throughout the day and night changes the structure and function of nicotinic receptors, stimulating intracellular processes of neuroadaptation.

The pharmacologic basis of nicotine addiction is thus a combination of positive reinforcements, such as enhancement of mood and mental or physical functioning, and avoidance of withdrawal symptoms when nicotine is not available. Figure 4 shows a typical daily smoking cycle.47

Figure 4
The Tobacco Addiction Cycle

Smokers tend to take in the same amount of nicotine from day to day to achieve the desired effects. They adjust their smoking behavior to compensate for changes in the availability of nicotine (e.g., when switching from regular to low-yield cigarettes) to regulate the body’s level of nicotine.48 Light smokers (those who smoke ≤5 cigarettes per day) and occasional smokers smoke primarily for the positive reinforcing effects of nicotine and have minimal or no withdrawal symptoms.49 They smoke primarily in association with particular activities (after eating a meal or while drinking alcohol), and are less likely to smoke in response to negative affect. Although withdrawal symptoms may not be prominent, many light and occasional smokers have difficulty quitting. Some of them have a high level of dependence, but with pharmacodynamics that differ from those in heavier smokers.

GENETICS OF NICOTINE ADDICTION

Studies in twins have shown a high degree of heritability of cigarette smoking (≥50%), including the level of dependence and the number of cigarettes smoked daily.50 These studies have also revealed the heritability of the particular symptoms that occur when a smoker stops smoking.51

Numerous attempts have been made to identify genes underlying nicotine addiction.50 Such studies are problematic because multiple genes and environmental factors determine complex behavior, and the many different dependence phenotypes may have different genetic underpinnings. Candidate genes coding for nicotine-receptor subtypes, dopamine receptors and dopamine transporters, GABA receptors, opiate and cannabinoid receptors, and other types of receptors have been associated with different aspects of smoking behavior.52 Subsequent research, however, has not replicated many of the initial findings.

Recent genomewide association studies point to several promising genetic determinants of nicotine dependence. Bierut et al. compared the genomes of smokers who became dependent on nicotine with the genomes of smokers who did not.53 Signals from genomewide association studies guided a second-phase candidate-gene association study by Saccone et al. in which several strong genetic associations were uncovered.54 Most prominent were genes within the α5/α3/β4 nicotinic cholinergic receptor gene complex on chromosome 15. This and other genomewide association studies of tobacco addiction have also identified genes affecting cell adhesion and extracellular matrix molecules, which are common among various addictions. These findings are consistent with the idea that neural plasticity and learning are key determinants of individual differences in vulnerability to nicotine dependence and other drug addictions.55

Variants associated with nicotine dependence in the α5/α3/β4 gene region (chromosome 15, 15q25) also have a significant association with the number of cigarettes smoked per day, plasma levels of cotinine (a biomarker of nicotine intake), urine levels of tobacco-smoke carcinogens, and the risks of smoking-related diseases.11,5662 The mechanisms of the associations between these variants and disease are probably related to the level of dependence and therefore the level of intake of tobacco-smoke toxins; however, nicotinic cholinergic receptors also modulate inflammatory responses, angiogenesis, and apoptosis, and thus account for additional mechanisms through which nicotine could affect the risk of disease.63

VULNERABILITY TO ADDICTION

Tobacco use typically begins in childhood or adolescence — 80% of smokers begin smoking by 18 years of age.64 Although two thirds of young people try cigarette smoking, only 20 to 25% of them become dependent daily smokers, usually as adults.65,66 Risk factors for smoking in childhood or adolescence include peer and parental influences, behavioral problems (e.g., poor school performance), personality characteristics (rebelliousness, risk taking, depression, and anxiety), and genetic influences.64

The risk of dependence increases when smoking begins early.64 Studies of the developing brain in animals suggest that nicotine can induce permanent changes that lead to addiction. Brain changes in adolescent rats exposed to nicotine are greater than those in exposed adult rats. Adolescent rats that have been exposed to nicotine have higher rates of nicotine self-administration as adults, which is consistent with the idea that early exposure to nicotine increases the severity of dependence.67,68

Tobacco addiction is highly prevalent among persons with mental illness or substance-abuse disorders.69,70 The mechanisms of this association are likely to include a shared genetic predisposition, the capacity of nicotine to alleviate some psychiatric symptoms, and the inhibitory effects of tobacco smoke on monoamine oxidase.23,71,72

Smoking behavior in women is more strongly influenced by conditioned cues and negative affect; men are more likely to smoke in response to pharmacologic cues, regulating their intake of nicotine more precisely than women.73 On average, women metabolize nicotine more quickly than men,74 which may contribute to their increased susceptibility to nicotine addiction and may help to explain why, among smokers, it is more difficult for women to quit.75

Insofar as smokers regulate their intake of nicotine to maintain particular levels throughout the day, those who metabolize nicotine rapidly take in more cigarette smoke per day than those who metabolize nicotine slowly. Nicotine is metabolized to cotinine primarily by the liver enzyme CYP2A6.76 Persons with a genetic basis for slow metabolism (those with variant CYP2A6 genes that are associated with reduced enzyme activity) smoke fewer cigarettes daily than persons with faster metabolism.77 The observation that the fraction of smokers with genetically slow metabolism in the population of smokers decreases with the increasing age of the cohort of smokers suggests that those with slow metabolism are more likely to quit than those with faster metabolism. Rapid metabolism of nicotine is associated with more severe withdrawal symptoms and a lower probability of success in quitting during nicotine-patch treatment.78,79

CONCLUSIONS

Nicotine sustains tobacco addiction, a major cause of disability and premature death, by acting on nicotinic cholinergic receptors in the brain to trigger the release of dopamine and other neurotransmitters. Release of dopamine, glutamate, and GABA is particularly important in the development of nicotine dependence, and CRF may play a key role in withdrawal. Neuroadaptation and tolerance involve changes in nicotinic receptors and neural plasticity. Nicotine addiction occurs when smokers come to rely on smoking to modulate mood and arousal, relieve withdrawal symptoms, or both. Light or occasional smokers smoke mainly for positive reinforcement in specific situations. Genetic studies indicate that nicotinic receptor subtypes and the genes involved in neuroplasticity and learning play a part in the development of dependence. People with psychiatric or substance-abuse disorders, who account for a large proportion of current smokers, have an increased susceptibility to tobacco addiction. Nicotine is metabolized primarily by the enzyme CYP2A6, and variation in the rate of nicotine metabolism contributes to differences in vulnerability to tobacco dependence and the response to smoking-cessation treatment. An increased understanding of the mechanisms of nicotine addiction has led to the development of novel medications (e.g., varenicline) that act on specific nicotinic receptor subtypes.80 The development of other drugs that act on nicotinic receptors and other mediators of nicotine addiction is likely to further enhance the effectiveness of smoking-cessation pharmacotherapy.

Acknowledgments

Supported by grants from the Flight Attendants Medical Research Institute and the National Institute on Drug Abuse (U.S. Public Health Service grants DA02277 and DA20830).

I thank Marc Olmsted for editorial assistance on an earlier version of the manuscript.

Footnotes

Disclosure forms provided by the author are available with the full text of this article at NEJM.org.

References

1. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ. 2004;328:1519. [PMC free article] [PubMed]
2. Cigarette smoking among adults and trends in smoking cessation — United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:1227–32. [PubMed]
3. Shiffman S, Scharf DM, Shadel WG, et al. Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers. J Consult Clin Psychol. 2006;74:276–85. [PubMed]
4. Carpenter CM, Wayne GF, Connolly GN. The role of sensory perception in the development and targeting of tobacco products. Addiction. 2007;102:136–47. [PubMed]
5. Dajas-Bailador F, Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci. 2004;25:317–24. [PubMed]
6. Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav. 2001;70:439–46. [PubMed]
7. Maskos U, Molles BE, Pons S, et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature. 2005;436:103–7. [PubMed]
8. Mineur YS, Picciotto MR. Genetics of nicotinic acetylcholine receptors: relevance to nicotine addiction. Biochem Pharmacol. 2008;75:323–33. [PMC free article] [PubMed]
9. Tapper AR, McKinney SL, Nashmi R, et al. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science. 2004;306:1029–32. [PubMed]
10. Tapia L, Kuryatov A, Lindstrom J. Ca2+ permeability of the (alpha4)3(beta2)2 stoichiometry greatly exceeds that of (alpha4)2(beta2)3 human acetylcholine receptors. Mol Pharmacol. 2007;71:769–76. [PubMed]
11. Bierut LJ, Stitzel JA, Wang JC, et al. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry. 2008;165:1163–71. [PMC free article] [PubMed]
12. Aberger K, Chitravanshi VC, Sapru HN. Cardiovascular responses to microinjections of nicotine into the caudal ventrolateral medulla of the rat. Brain Res. 2001;892:138–46. [PubMed]
13. Levin ED, Bettegowda C, Blosser J, Gordon J. AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. Behav Pharmacol. 1999;10:675–80. [PubMed]
14. Hajós M, Hurst RS, Hoffmann WE, et al. The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther. 2005;312:1213–22. [PubMed]
15. Mansvelder HD, McGehee DS. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron. 2000;27:349–57. [PubMed]
16. Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol. 2002;53:606–17. Idem. [PubMed]
17. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 1997;20:92–8. [PubMed]
18. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci. 2005;8:1445–9. [PubMed]
19. Kenny PJ, Markou A. Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. Neuropsychopharmacology. 2006;31:1203–11. [PubMed]
20. Brody AL. Functional brain imaging of tobacco use and dependence. J Psychiatr Res. 2006;40:404–18. [PMC free article] [PubMed]
21. Hollander JA, Lu Q, Cameron MD, Kamenecka TM, Kenny PJ. Insular hypocretin transmission regulates nicotine reward. Proc Natl Acad Sci U S A. 2008;105:19480–5. [PubMed]
22. Fowler JS, Logan J, Wang GJ, Volkow ND. Monoamine oxidase and cigarette smoking. Neurotoxicology. 2003;24:75–82. [PubMed]
23. Lewis A, Miller JH, Lea RA. Monoamine oxidase and tobacco dependence. Neurotoxicology. 2007;28:182–95. [PubMed]
24. Wang H, Sun X. Desensitized nicotinic receptors in brain. Brain Res Brain Res Rev. 2005;48:420–37. [PubMed]
25. Govind AP, Vezina P, Green WN. Nicotine-induced upregulation of nicotinic receptors: underlying mechanisms and relevance to nicotine addiction. Biochem Pharmacol. 2009;78:756–65. [PMC free article] [PubMed]
26. Dani JA, Harris RA. Nicotine addiction and comorbidity with alcohol abuse and mental illness. Nat Neurosci. 2005;8:1465–70. [PubMed]
27. Brody AL, Mandelkern MA, London ED, et al. Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry. 2006;63:907–15. [PMC free article] [PubMed]
28. Balfour DJ. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens. Nicotine Tob Res. 2004;6:899–912. [Erratum, Nicotine Tob Res 2005;7:307.] [PubMed]
29. Le Moal M, Koob GF. Drug addiction: pathways to the disease and pathophysiological perspectives. Eur Neuropsychopharmacol. 2007;17:377–93. [PubMed]
30. George O, Ghozland S, Azar MR, et al. CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. Proc Natl Acad Sci U S A. 2007;104:17198–203. [PubMed]
31. Knott V, Heenan A, Shah D, Bolton K, Fisher D, Villeneuve C. Electrophysiological evidence of nicotine’s distracter-filtering properties in non-smokers. J Psychopharmacol. 2009 November 25; (Epub ahead of print) [PubMed]
32. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43:289–94. [PubMed]
33. Hughes JR. Clinical significance of tobacco withdrawal. Nicotine Tob Res. 2006;8:153–6. [PubMed]
34. Koob GF, LeMoal M. Drug abuse: hedonic homeostatic dysregulation. Science. 1997;278:52–8. [PubMed]
35. Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron. 1996;16:905–8. [PubMed]
36. Kauer JA, Malenka RC. Synaptic plasticity and addiction. Nat Rev Neurosci. 2007;8:844–58. [PubMed]
37. Davis JA, Gould TJ. Associative learning, the hippocampus, and nicotine addiction. Curr Drug Abuse Rev. 2008;1:9–19. [PubMed]
38. Olausson P, Jentsch JD, Taylor JR. Repeated nicotine exposure enhances responding with conditioned reinforcement. Psychopharmacology (Berl) 2004;173:98–104. [PubMed]
39. Kenny PJ, Markou A. Conditioned nicotine withdrawal profoundly decreases the activity of brain reward systems. J Neurosci. 2005;25:6208–12. [PubMed]
40. Rose JE, Behm FM, Levin ED. Role of nicotine dose and sensory cues in the regulation of smoke intake. Pharmacol Biochem Behav. 1993;44:891–900. [PubMed]
41. Rose JE, Behm FM, Westman EC, Johnson M. Dissociating nicotine and non-nicotine components of cigarette smoking. Pharmacol Biochem Behav. 2000;67:71–81. [PubMed]
42. Naqvi NH, Rudrauf D, Damasio H, Bechara A. Damage to the insula disrupts addiction to cigarette smoking. Science. 2007;315:531–4. [PubMed]
43. Samaha AN, Yau WY, Yang P, Robinson TE. Rapid delivery of nicotine promotes behavioral sensitization and alters its neurobiological impact. Biol Psychiatry. 2005;57:351–60. [PubMed]
44. Houtsmuller EJ, Henningfield JE, Stitzer ML. Subjective effects of the nicotine lozenge: assessment of abuse liability. Psychopharmacology (Berl) 2003;167:20–7. [PubMed]
45. Henningfield JE, Benowitz NL, Connolly GN, et al. Reducing tobacco addiction through tobacco product regulation. Tob Control. 2004;13:132–5. [PMC free article] [PubMed]
46. Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend. 1993;33:23–9. [PubMed]
47. Benowitz NL. Compensatory smoking of low yield cigarettes. In: Shopland DR, Burns DM, Benowitz NL, Amacher RH, editors. Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. Bethesda, MD: National Institutes of Health; 2001. p. 3964. (NIH publication no. 02–5074.)
48. Cigarette smoking and nicotine addiction. Med Clin North Am. 1992;76:415–37. Idem. [PubMed]
49. Shiffman S. Light and intermittent smokers: background and perspective. Nicotine Tob Res. 2009;11:122–5. [PMC free article] [PubMed]
50. Lessov-Schlaggar CN, Pergadia ML, Khroyan TV, Swan GE. Genetics of nicotine dependence and pharmacotherapy. Biochem Pharmacol. 2008;75:178–95. [PMC free article] [PubMed]
51. Xian H, Scherrer JF, Madden PA, et al. Latent class typology of nicotine withdrawal: genetic contributions and association with failed smoking cessation and psychiatric disorders. Psychol Med. 2005;35:409–19. [PubMed]
52. Ho MK, Tyndale RF. Overview of the pharmacogenomics of cigarette smoking. Pharmacogenomics J. 2007;7:81–98. [PubMed]
53. Bierut LJ, Madden PA, Breslau N, et al. Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet. 2007;16:24–35. [PMC free article] [PubMed]
54. Saccone SF, Hinrichs AL, Saccone NL, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet. 2007;16:36–49. [PMC free article] [PubMed]
55. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE. Molecular genetics of nicotine dependence and abstinence: whole genome association using 520,000 SNPs. BMC Genet. 2007;8:10. [PMC free article] [PubMed]
56. Berrettini W, Yuan X, Tozzi F, et al. Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry. 2008;13:368–73. [PMC free article] [PubMed]
57. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452:638–42. [PubMed]
58. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 2008;40:616–22. [PMC free article] [PubMed]
59. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452:633–7. [PubMed]
60. Pillai SG, Ge D, Zhu G, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet. 2009;5(3):e1000421. [PMC free article] [PubMed]
61. Le Marchand L, Derby KS, Murphy SE, et al. Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. Cancer Res. 2008;68:9137–40. [PMC free article] [PubMed]
62. Keskitalo K, Broms U, Heliövaara M, et al. Association of serum cotinine level with a cluster of three nicotinic acetylcholine receptor genes (CHRNA3/CHRNA5/CHRNB4) on chromosome 15. Hum Mol Genet. 2009;18:4007–12. [PMC free article] [PubMed]
63. Thunnissen FB. Acetylcholine receptor pathway and lung cancer. J Thorac Oncol. 2009;4:943–6. [PubMed]
64. Lynch BS, Bonnie RJ. Growing up tobacco free — preventing nicotine addiction in children and youths. Washington, DC: National Academy Press; 1994. The nature of nicotine addiction; pp. 28–68.
65. Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the future: national survey results on drug use, 1975–2006. Bethesda, MD: National Institute on Drug Abuse; 2007. (NIH publication no. 07–6205.)
66. Kandel D, Schaffran C, Griesler P, Samuolis J, Davies M, Galanti R. On the measurement of nicotine dependence in adolescence: comparisons of the mFTQ and a DSM-IV-based scale. J Pediatr Psychol. 2005;30:319–32. [PMC free article] [PubMed]
67. Placzek AN, Zhang TA, Dani JA. Age dependent nicotinic influences over dopamine neuron synaptic plasticity. Biochem Pharmacol. 2009;78:686–92. [PMC free article] [PubMed]
68. Dwyer JB, McQuown SC, Leslie FM. The dynamic effects of nicotine on the developing brain. Pharmacol Ther. 2009;122:125–39. [PMC free article] [PubMed]
69. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284:2606–10. [PubMed]
70. Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict. 2005;14:106–23. [PMC free article] [PubMed]
71. Ziedonis D, Hitsman B, Beckham JC, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res. 2008;10:1691–715. [PubMed]
72. Martin LF, Freedman R. Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol. 2007;78:225–46. [PubMed]
73. Perkins KA, Jacobs L, Sanders M, Caggiula AR. Sex differences in the subjective and reinforcing effects of cigarette nicotine dose. Psychopharmacology (Berl) 2002;163:194–201. [PubMed]
74. Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P., III Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther. 2006;79:480–8. [PubMed]
75. Perkins KA, Scott J. Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob Res. 2008;10:1245–50. [PubMed]
76. Hukkanen J, Jacob P, III, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57:79–115. [PubMed]
77. Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther. 2005;77:145–58. [PubMed]
78. Lerman C, Tyndale R, Patterson F, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther. 2006;79:600–8. [PubMed]
79. Rubinstein ML, Benowitz NL, Auerback GM, Moscicki AB. Rate of nicotine metabolism and withdrawal symptoms in adolescent light smokers. Pediatrics. 2008;122(3):e643–e647. [PMC free article] [PubMed]
80. Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the alpha-4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology. 2007;52:985–94. [PubMed]